DDInter1652 DDInter546
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions . Dienogest is commonly marketed as Visanne, Natazia and Qlaira.
Dienogest {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cladribine
Dienogest {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Dienogest {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Dienogest {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Cladribine
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Dienogest may lead to a major life threatening interaction when taken with Griseofulvin
Dienogest may lead to a major life threatening interaction when taken with Encorafenib